fashion -WSS

fashion

author：focus 2025-09-03 22:38:22 - browse：1467

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： How the BIOSECURE Act is already affecting U.S., Chinese life science firms

explore

WSS

A new nitrogen execution bill also undermines medical licensing

STAT Virtual Event: ASCO Recap, Live!

Why palliative psychiatry is worth discussing

Statins may not be needed by millions of people, study suggests

Coercive sterilizations revealed by STAT prompt outrage

Moderna says combo Covid

hotspot

fashion

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

After affirmative action ruling, medical educators look to 'holistic review'

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

New air purifier tech could be key to improving indoor air quality

Coercive sterilizations revealed by STAT prompt outrage

DIEP, the 'gold standard' of breast reconstruction, is under threat

R1 RCM gets $5.8 billion buyout offer from private equity firm

Continuity nursing helped my family in our darkest PICU moments

Readers discuss the intersection of pregnancy and addiction

entertainment

NIH tests clinical research in primary care with $30 million program

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Teladoc has a new CEO, but challenges remain the same

Cheap, fast test for Zika and dengue could cost just $1

ALS patient reclaims some autonomy thanks to wearable 'robot'

Alabama frozen embryo ruling has major implications for IVF clinics

explore

knowledge

explore

explore